AMPEL BioSolutions, LLC

AMPEL BioSolutions is a growth-stage precision medicine company with a proprietary genomic platform, tools and machine learning algorithms. Profitability from in-house clinical trial design/management fueled R&D for LuGENE®, a gene-based prognostic for lupus patients to predict disease status & match patients with best drug options. Current customers are Pharma to accelerate trial success by enrolling patients into trials that express drug target/pathway. AMPEL is currently engaged with investors to funds to scale and commercialize LuGENE® for the decision support markets (MD/patient and payors). AMPEL's technology extends into diseases involving the immune system and inflammation, including oncology and infectious disease.